代谢综合征各组分与非酒精性脂肪性肝病进展的关联
基于非酒精性脂肪性肝炎临床研究网络多中心前瞻性队列(2002-2022)的事后分析,纳入452例经活检证实的非酒精性脂肪性肝病患者,中位随访4.3年。代谢综合征与基线组织学更严重相关,但与纤维化进展或消退无关;糖耐量异常/糖尿病与纤维化进展风险升高相关,高血压与纤维化进展风险降低相关。
要点
- 代谢综合征与基线更严重的组织学损伤相关,但非疾病进展或消退的危险因素。
- 糖耐量异常/糖尿病与纤维化进展风险升高相关(校正HR=1.61)。
- 高血压与纤维化进展风险降低相关(校正HR=0.64)。
核心结论
- 在非酒精性脂肪性肝病患者队列中,代谢综合征与基线组织学更严重相关,但不是疾病进展或消退的危险因素。
- 糖耐量异常/糖尿病与纤维化进展率较高相关,高血压与纤维化进展率较低相关。
研究设计与样本
- 多中心前瞻性队列研究的事后分析,使用非酒精性脂肪性肝炎临床研究网络非干预注册(2002-2022年)。
- 纳入452例年龄18岁及以上、经活检证实的非酒精性脂肪性肝病患者;平均年龄51岁,三分之一为男性,85%为白人;中位随访4.3年(范围1-15.6年)。
主要发现
- 代谢综合征与纤维化进展或消退无显著关联。
- 糖耐量异常/糖尿病与纤维化进展风险升高相关(校正风险比=1.61;95%置信区间:1.11-2.34)。
- 高血压与纤维化进展风险降低相关(校正风险比=0.64;95%置信区间:0.43-0.96)。
- 基线时,代谢综合征、腰围增大和糖耐量异常/糖尿病患者的气球样变和纤维化评分更差,明确非酒精性脂肪性肝炎患病率更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The effects of metabolic syndrome (MetS), its individual components, and baseline liver histology, on the rates of progression and regression of nonalcoholic fatty liver disease (NAFLD), were evaluated. METHODS: We conducted a post hoc analysis of a multicenter prospective cohort study using the noninterventional registry of the Nonalcoholic Steatohepatitis Clinical Research Network (2002-2022). We included patients aged 18 years or older with biopsy-proven NAFLD. Outcomes included progression/regression of histology defined by changes in NAFLD Activity Score, nonalcoholic steatohepatitis, or fibrosis. Crude incidence rates were compared among patients with MetS vs those without using Kaplan-Meier curves and log-rank test. Cox proportional hazard models were used to estimate effects of MetS and its components on the fibrosis progression/regression. RESULTS: We included 452 patients; the mean age was 51 years, one-third was male, and 85% was White. The median follow-up was 4.3 (range: 1-15.6) years. At baseline, patients with MetS, large waist circumference, and impaired glucose tolerance/diabetes had worse ballooning and fibrosis scores and a higher prevalence of definite nonalcoholic steatohepatitis than those without. MetS was not associated with fibrosis progression or regression. Impaired glucose tolerance/diabetes was associated with a higher risk of fibrosis progression (adjusted hazard ratio = 1.61; 95% confidence interval: 1.11-2.34) whereas hypertension was associated with a lower risk (adjusted hazard ratio = 0.64; 95% confidence interval: 0.43-0.96). DISCUSSION: In the cohort of patients with NAFLD, MetS was associated with greater histological severity at baseline but was not a risk factor of disease progression or regression. Impaired glucose/diabetes was associated with a higher rate and hypertension with a lower rate of fibrosis progression.
引用
- Le P, Tatar M, Rothberg MB, et al. Association of Components of Metabolic Syndrome and the Progression of Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2025. PMID: 40163040. doi:10.14309/ajg.0000000000003455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。